

HTG MOLECULAR DIAGNOSTICS, INC  
Form SC 13G  
November 22, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. \_\_\_)\*  
HTG Molecular Diagnostics, Inc.  
(Name of Issuer)  
Common Stock, \$0.001 par value  
(Title of Class of Securities)  
40434H 104  
(CUSIP Number)  
November 17, 2016  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

SCHEDULE 13G  
CUSIP No. 40434H 104

Names of Reporting

- 1 Person:  
QIAGEN N.V.  
Check the appropriate box  
if a member of a Group  
2 (see instructions)  
(a)   
(b)   
3 SEC Use Only

Citizenship or Place of  
4 Organization

- The Netherlands  
5 ~~Number~~ of ~~Shares~~ Voting Power  
of 833,333  
6 ~~Number~~ of ~~Shares~~ Shared Voting Power  
Beneficially  
7 ~~Number~~ of ~~Shares~~ Dispositive Power  
by 833,333  
8 ~~Number~~ of ~~Shares~~ Shared Dispositive Power  
Reporting  
Person  
With:

- Aggregate Amount  
9 Beneficially Owned by  
Each Reporting Person  
833,333  
Check box if the aggregate  
amount in row (9) excludes  
10 certain shares (See  
Instructions)  
  
Percent of class represented  
11 by amount in row (9)  
10.6%  
Type of Reporting Person  
12 (See Instructions)  
FI



SCHEDULE 13G  
CUSIP No. 40434H 104

Names of Reporting  
Person:  
1 QIAGEN North American  
Holdings, Inc.  
Check the appropriate box  
if a member of a Group  
2 (see instructions)  
(a)   
(b)   
3 SEC Use Only

Citizenship or Place of  
4 Organization  
California  
Number of ~~Shares~~ Voting Power  
5 of 0 <sup>(1)</sup>  
Number of ~~Shares~~ Shared Voting Power  
6 Beneficially  
Owned ~~by~~ Dispositive Power  
7 by 0 <sup>(1)</sup>  
Number of ~~Shares~~ Shared Dispositive Power  
8 Reporting  
Person  
With:

Aggregate Amount  
9 Beneficially Owned by  
Each Reporting Person  
0 <sup>(1)</sup>  
Check box if the aggregate  
amount in row (9) excludes  
10 certain shares (See  
Instructions)  
  
Percent of class represented  
11 by amount in row (9)

Type of Reporting Person  
12 (See Instructions)  
CO

<sup>(1)</sup>The 833,333 shares of  
Common Stock of the Issuer  
are held of record by  
QIAGEN North American  
Holdings, Inc., a  
wholly-owned subsidiary of  
QIAGEN N.V.



Item 1.

- (a) Name of Issuer: HTG Molecular Diagnostics, Inc.
- (b) Address of Issuer's Principal Executive Offices: 3430 E. Global Loop, Tucson, Arizona 85706

Item 2.

- (a) Name of Person Filing: QIAGEN N.V.
- (b) Address of Principal Business Office or, if None, Residence: Hulsterweg 82, 5912 PL Venlo, The Netherlands
- (c) Citizenship: The Netherlands
- (d) Title and Class of Securities: Common Stock, par value \$0.001 per share.
- (e) CUSIP No.: 40434H 104

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is  
a:

Not applicable as this Schedule is filed pursuant to Rule 13d-1(c).

Item 4. Ownership

- (a) Amount Beneficially Owned: 833,333
- (b) Percent of Class: 10.6%
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: 833,333
  - (ii) Shared power to vote or to direct the vote:
  - (iii) Sole power to dispose or to direct the disposition of: 833,333
  - (iv) Shared power to dispose or to direct the disposition of:

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of more than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

The shares of Common Stock of the Issuer were acquired by and are held of record by QIAGEN North American Holdings, Inc., a wholly owned subsidiary of QIAGEN N.V.

Item 8. Identification and classification of members of the group.

See Item 7.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 22, 2016

QIAGEN  
N.V.  
QIAGEN  
North  
American  
Holdings,  
Inc.

By:

/s/ Roland  
Sackers  
Roland  
Sackers  
Chief  
Financial  
Officer